Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy
The Oncologist · 08.07.2026 · 31 (8)
DOI: 10.1093/oncolo/oyag272 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 14.07.2026. Verfasst von Kyle Murchison und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, 33431, United States. Hauptthemen laut MEDLINE: Cutaneous Squamous Cell Carcinoma, Neoadjuvant Therapy, Programmed Cell Death 1 Receptor, Hematologic Neoplasms. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dargie Family Fund at Dana-Farber Cancer Institute.
Abstract (Originalsprache)
Background
Patients with cutaneous squamous cell carcinoma (CSCC) and concurrent hematologic malignancy are underrepresented in clinical trials of anti-programmed death-1 (PD1) therapy due to concerns about efficacy and safety. The objective of this study is to evaluate clinical outcomes and safety of neoadjuvant anti-PD1 in patients with CSCC and concurrent hematologic malignancy.
Methods
This is a retrospective single-institution cohort study of neoadjuvant-intent anti-PD-1 therapy in patients with advanced CSCC and a concurrent hematologic malignancy. Patient and tumor characteristics are described. Clinical and pathologic response to anti-PD-1 therapy, safety, and CSCC recurrence risk and disease-specific survival are reported.
Results
Ten patients with CSCC and a concurrent hematologic malignancy received immunotherapy with neoadjuvant intent. All patients were treated with cemiplimab, and 4/10 patients experienced a response by composite assessment of clinical, radiographic, and pathologic data. Two of eight patients who underwent planned surgical resection had a complete pathologic response, and 2 of 2 patients who did not undergo surgery had a clinical response on radiographic/clinical assessment. Three patients were receiving active treatment for hematologic malignancy during immunotherapy; of these, one demonstrated a clinical and pathologic response. One patient experienced a grade 3 immune-related adverse event (arthritis).
Conclusion
The results suggest that anti-PD-1 therapy in the neoadjuvant setting in patients with CSCC and with concurrent hematologic malignancy is feasible. The clinical outcomes observed in this small cohort highlight the need for prospective studies of patients with concurrent hematologic malignancy in future neoadjuvant CSCC trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, 33431, United States.
- Department of Dermatology, Brigham and Women's Hospital, Boston, MA, 02215, United States.
- Division of Hematology and Oncology, Department of Medicine,Dana-Farber Cancer Institute, Boston, MA, 02215, United States.
- Harvard Medical School, Boston, MA, 02215, United States.
- University of Massachusetts Chan Medical School, Worcester, MA, 01655, United States.
- University of Michigan, Department of Dermatology, Ann Arbor, MI, 48109, United States.
ORCID-Profile: Karam Khaddour, Charles Yoon, Emily Y Kim, Ann W Silk
Förderung
- Dargie Family Fund at Dana-Farber Cancer Institute
Zitieren
APA
Murchison, K., Khaddour, K., Camargo, A., Ruiz, E., Sethi, R., Rettig, E., Yoon, C., Kim, E. Y., DeSimone, M., Cohen, J., LeBoeuf, N. R., Ran, N., Thakuria, M., & Silk, A. W. (2026). Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag272
Vancouver
Murchison K, Khaddour K, Camargo A, Ruiz E, Sethi R, Rettig E, et al. Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag272
BibTeX
@article{Murchison2026,
author = {Murchison, Kyle and Khaddour, Karam and Camargo, Anthony and Ruiz, Emily and Sethi, Rosh and Rettig, Eleni and Yoon, Charles and Kim, Emily Y and DeSimone, Mia and Cohen, Justine and LeBoeuf, Nicole R and Ran, Nina and Thakuria, Manisha and Silk, Ann W},
title = {Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy},
journal = {The Oncologist},
year = {2026},
volume = {31},
number = {8},
doi = {10.1093/oncolo/oyag272}
}
EUVIMED